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ABSTRACT Gastrointestinal stromal tumor (GIST) is
the most common sarcoma arising in the gastrointestinal
(GI) tract. Imatinib mesylate (imatinib) is efficacious in
treating advanced and metastatic GIST. Patients undergo-
ing resection of GIST realize a highly variable median
disease-free survival (DFS). In the absence of prospective
data, we conducted a randomized, phase II study to assess
the safety and efficacy of preoperative and postoperative
imatinib for the treatment of GIST. Nineteen GIST patients
undergoing surgical resection were randomized to receive
3, 5, or 7 days of preoperative imatinib (600 mg daily).
Patients received postoperative imatinib for 2 years. Peri-
operative adverse events were compared with those in an
imatinib-naı¨ve historical control. The efficacy of imatinib
was assessed by 18fluorodeoxyglucose positron emission
tomography (18FDG-PET), dynamic computed tomography
(dCT), terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assay, and DFS. Imatinib did not
affect surgical morbidity as compared with an imatinib-
naı¨ve cohort (p C 0.1). Most patients responded to
preoperative imatinib by 18FDG-PET and dCT (69% and
71%, respectively). Tumor cell apoptosis increased by an
average of 12% (range 0–33%) and correlated with the
duration of preoperative imatinib (p = 0.04). Median DFS
of patients treated with surgery and imatinib was
46 months (range 10–46 months). Tumor size was a pre-
dictor of recurrence after postoperative imatinib
(p = 0.02). Imatinib appears to be safe and may be con-
sidered for patients undergoing surgical resection of their
GIST. Radiographic response and tumor cell apoptosis
occur within the first week of imatinib therapy.
Gastrointestinal stromal tumor (GIST) is the most com-
mon sarcoma arising in the GI tract and shares features with
the interstitial cell of Cajal, the pacemaker cell of the GI
tract.1,2 Most GISTs encode activating mutations in either
the kit or platelet-derived growth factor receptor-a (PDGFR-
a) gene, an important genetic event in tumorigenesis.3,4
The use of imatinib mesylate (imatinib; GleevecTM;
Novartis, Basel, Switzerland) has revolutionized the man-
agement of advanced GIST. Imatinib inhibits the kinase
activity of kit, PDGFR-a, and the breakpoint cluster region
(BCR)/Abelson (ABL) fusion protein.5 Median overall sur-
vival for patients with advanced GIST treated with imatinib
was longer than 57 months, compared with 9 months for
doxorubicin-treated, historical controls.6,7
Approximately 46% of all GIST patients are surgical
candidates, but 40–90% suffer recurrence within 24 months
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of complete resection with median disease-free survival
(DFS) as low as 18 months.8–12 Thus, a substantial subset of
patients may benefit from combined surgery and imatinib.
Prospective data on the safety and efficacy of preoperative,
perioperative, and postoperative imatinib remain limited.
Additionally, there are no prospective studies demonstrat-
ing the efficacy of imatinib during the first week of therapy,
nor studies to determine whether imatinib’s mechanism of
action involves tumor cell apoptosis.
Herein, we present the first randomized, phase II study
of preoperative and postoperative imatinib for patients with
GIST undergoing surgical resection. The objectives of this
study were to determine the safety and efficacy of imatinib
administered for 3, 5, or 7 days prior to surgery and con-
tinued for 24 months postoperatively as well as to
determine whether the antitumor activity of imatinib was
associated with induction of tumor cell apoptosis.
PATIENTS AND METHODS
Patients eligible for this study had histologically proven
diagnosis of kit-expressing GIST C 1 cm in greatest
diameter never treated with any previous chemotherapy
including imatinib for which surgical resection was rec-
ommended by an experienced sarcoma surgeon (KK.H.
and R.E.P.). Informed consent was obtained from all
patients under a protocol approved by an institutional
review board (IRB).
Upon accrual, patients were randomized to receive 3, 5,
or 7 days of imatinib (300 mg twice daily by mouth) pre-
operatively, with the last dose of imatinib given the
morning of surgery. Patients restarted imatinib therapy
postoperatively and continued it for 2 years at the 600 mg
daily dosage (the highest dosage of imatinib approved by
the United States Food and Drug Administration). Patients
were assessed for adverse events using the Common Ter-
minology Criteria for Adverse Events version 3.0.13
This trial was designed for 24 patients in order to
achieve the probability of a 2-year disease-free survival
reaching an acceptable posterior 90% credible interval.
Due to slow accrual, 19 patients were evaluated for out-
comes. Patients were randomized in a blinded fashion by
our institutional department of biostatistics using an IRB-
approved schema (P.T.).
The primary endpoint of this study was tumor cell
apoptosis. The secondary endpoints were patient safety,
DFS, and radiographic response.
Retrospective Imatinib-Naı¨ve Cohort
In order to better characterize surgical morbidity in this
patient cohort, we collected, and compared, data from a
retrospective series of GIST patients treated at our
institution undergoing complete resection of their GIST
who were not treated with preoperative nor postoperative
imatinib. Surgical parameters including estimated blood
loss, perioperative complications, and stage of disease were
compared with the patients treated on the current pro-
spective study.
Pre-Imatinib Biopsy and Surgical Resection
All patients were requested to undergo an image-guided
[ultrasound or computed tomography (CT)] core needle or
endoscopic biopsy of the radiographically viable portion of
tumor within 4 weeks prior to initiation of imatinib treat-
ment. Once completing the allocated duration of
preoperative imatinib, patients underwent exploratory lap-
arotomy and maximal resection with the attempt to remove
all gross disease. Viable tissue was processed rapidly by
formalin fixation or Optimal Cutting Temperature com-
pound (OCT; Electron Microscopy Sciences, Hatfield, PA,
USA). Disease stage was assessed by patient history and
extent of disease as evidenced by radiographic imaging.
GIST Genotyping
Tumor tissue was assayed for kit and PDGFR-a muta-
tion as previously described.4,14 Genomic DNA samples
were isolated from paraffin-embedded or frozen tissue,
polymerase chain reaction was performed, and mutations
were identified by a 3730 9 1 DNA Analyzer (Applied
Biosystems, Foster City, CA) at MDACC Nucleic Acid
Core Facility.
18Fluorodeoxyglucose Positron Emission Tomography
(18FDG PET)
Patients underwent 18FDG PET imaging before and after
preoperative imatinib therapy using a CTI HR ? PET
scanner (Siemens inc., Knoxville, TN) following adminis-
tration of 10–15 mCi 18FDG over 1 min as described
previously.15 Scans performed during preoperative imati-
nib were obtained within 24 h of surgical resection.
Briefly, patients underwent a 60-min uptake phase, a 5-
min emission scan, and a 3-min transmission scan per field
of view in a two-dimensional mode. Images were inter-
preted using volumetric and multiple orthogonal projection
analysis then quantitated using vendor specific software.
Maximal standardized uptake value (SUVmax) was mea-
sured from a region of interest (ROI) representative of
tumor on pretreatment images and corresponding ROIs on
posttreatment images. Since there is no standardized cri-
teria for PET response at 3, 5, or 7 days after initiation of
imatinib for GIST, PET response was defined as either a
residual SUVmax B 3.9 in post-imatinib scans or a relative
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40% decrease in SUVmax between pre and post-imatinib
scans.15
Dynamic (Perfusion) Computed Tomography (dCT)
dCT was performed before and after preoperative i-
matinib (within 24 h of surgical resection). All image data
were acquired on a Light-Speed or Hi-Speed Advantage
helical scanner with multidetector rows (GE Medical
Systems, Milwaukee, WI, USA). Fifty milliliters nonionic
contrast material (Optiray 320; Mallinckrodt Inc., St.
Louis, MO) was injected at a rate of 5 mL/s through an 18-
gauge needle in the antecubital fossa. Four 5-mm-thickness
slices were obtained through the ROIs with a 5–10 s delay
and 30–40 s scan time in CINE mode. Imaging data were
postprocessed at an Advanced Workstation (AW HE
Healthcare) to calculate the perfusion parameters (blood
flow: mL/min/100 g tissue) for all four cross-sections. The
mean values of blood flow from all four cross-sections
were calculated for response evaluation. dCT response was
defined as a decrease in tumoral blood flow C 10%.
TUNEL Assay
Frozen tissue from biopsy and surgical specimens was
assayed for apoptosis using the DeadEnd Fluorometric
TUNEL system (Promega Corporation, Madison, WI,
USA). Using Spot Advanced for Windows and Image
ProPLUS version 6.1 for Windows software, five random
fields of view at 200 9 magnification were visualized, and
cells were counted to determine the percentage of TUNEL-
positive nuclei. The average percentage of TUNEL-posi-
tive cells in biopsy and surgical tissues were compared.
Statistical Analyses
Cox survival regression models were used to assess the
effects of tumor size, patient age, and sex on DFS.16
Univariate Cox survival regression models were used to
assess the individual effects of changes in 18FDG PET,
dCT, and apoptosis on DFS.16 Kruskal–Wallis tests were
used to determine between-group differences in dCT,
18FDG PET, and apoptosis. Martingale residual plots were
employed to examine possible functional forms of contin-
uous variables in the fitted Cox models. Owing to the
limited sample size (six cases of disease progression in 19
patients), a multivariate Cox model was not fit. Linear
regression was used to determine the correlation between
dCT and/or 18FDG PET and apoptosis response. Unad-
justed DFS time probabilities were estimated using the
method of Kaplan and Meier.17 Survival plots and actuarial
life tables were constructed using SPSS version 11.0 for
Mac OS X. An extended Cox model with time-varying
covariates was employed to examine the effect of imatinib
on DFS. Covariate distributions for this cohort and the
retrospective patients were compared using generalized
Fisher exact tests for categorical variables and Wilcoxon
tests for numerical valued variables.18
Role of Funding Source
No funding source (including Novartis) had input in the
collection, analysis, and interpretation of data. Novartis did
review this manuscript and concurred with the decision to
submit this paper for publication.
RESULTS
Patient Characteristics Including Tumor Mutation
Status
Nineteen patients were accrued from August 8, 2003, to
March 26, 2007, at MDACC, TX, USA. The trial sche-
matic is illustrated in Supplemental Data 1. The baseline
patient characteristics are provided in Table 1.
Baseline core needle biopsies of tumor were collected
prior to imatinib treatment from 14 (74%) of 19 patients.
We did not acquire tumor tissue by core-needle biopsy at
baseline from five patients owing to lack of consent or
untoward risk of biopsy.
Mutation analyses revealed 18 (95%) patients had tumor
harboring mutations in either kit or PDGFR-a (Table 1).
Interestingly, one patient had both a kit exon 11 duplication
and a PDGFR-a exon 12 point mutation. The most com-
mon type of mutation was deletion (47% of patients,
Supplemental Data 2).
Surgical Intervention and Perioperative Morbidity
Seventeen of 19 patients underwent a timely resection of
their GIST after receiving imatinib. In one patient, the
surgical resection was delayed by 3 weeks owing to i-
matinib-associated toxicity. One patient withdrew consent
prior to surgical resection for personal reasons not related
to the trial.
The surgical procedures are summarized in Table 2A.
All patients had exploratory laparotomy and en bloc
resection of tumor and pseudo-capsule, with resection of
any gross metastatic deposits.
There were no cases of intraoperative tumor rupture or
hemorrhage. Additionally, we observed no episodes of
wound dehiscence or delayed healing. One patient had a
pelvic abscess that was drained percutaneously and resolved
on antibiotic therapy. Three (18%) of 17 patients required
brief (\3 days) care in the intensive care unit: need for
serum glucose monitoring secondary to type I diabetes
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mellitus, a non-Q-wave myocardial ischemic event on
postoperative day 1, and hyperglycemia secondary to type
II diabetes mellitus. Patients began postoperative imatinib a
median of 22 days (range 7–59 days) after tumor resection.
As compared with a retrospective analysis of 27 imati-
nib-naı¨ve patients undergoing surgical resection, similar
mean estimated blood loss (605.8 mL, p = 0.58), transfu-
sion rates (p = 1.0), and perioperative complication rates
(p = 0.1) were demonstrated (Table 2B).
Medical Intervention and Adverse Events
The toxicity profile of imatinib in this clinical trial was
similar to that in patients with metastatic GIST
(Table 3).6,19 Most patients tolerated therapy well, and
there were no deaths. Five grade 4 events occurred in four
(22%) patients. Perioperative vascular events were infre-
quent (12%, 2 of 17 patients), but one patient had non-Q-
wave myocardial ischemia and one patient had a transient
ischemic event. Both patients had known, pre-existing
vascular disease and both fully recovered to baseline
function prior to discharge from the hospital. One patient
had grade 4 anemia postoperatively secondary to endo-
metriosis and uterine bleeding.
Radiographic Efficacy of Preoperative Imatinib
Sixteen (84%) of 19 patients were assessable for
response by 18FDG PET (Fig. 1). One patient did not
complete the imaging studies owing to scheduling errors.
Two patients had tumors that did not demonstrate glucose
uptake on baseline 18FDG PET. Eleven (69%) of 16
patients had tumors that demonstrated C 40% decrease in
SUVmax. Moreover, 10 (63%) of 16 patients had tumors
with residual SUVmax B 3.9.
Seventeen (89%) of 19 patients had GISTs that were
assessable by dCT (Fig. 1). Two patients did not complete
the imaging studies because of scheduling errors. Of these
17 patients, 12 (71%) had a [10% (range 11.53–75.14%)
decrease in blood flow in the viable regions of their tumors.
Collectively, all patients that were assessed for radio-
graphic response responded to preoperative imatinib by
one or more of our criteria. Interestingly, 62% of patients
responded exclusively by either a decrease in tumor cell
glucose metabolism (PET) or by a decrease in tumor blood
flow (dCT) but not both, whereas only 38% responded by
both modalities. Thus, we next sought to determine the
early cellular effects of imatinib.
Antitumor Efficacy of Preoperative Imatinib
To better understand the tumoral events leading to the
radiographic responses evidenced by 18FDG PET and dCT,
we comparatively analyzed matched baseline core-needle
biopsies and surgical specimens using light microscopy
(Fig. 2).
Histologically, equivalently cellular tumor tissue was
seen at both baseline and surgery without evidence of
myxoid degeneration, a feature characteristic of more
prolonged treatment with imatinib. Thus, pathologic
response and cytoreduction after this short interval of
preoperative imatinib was not appreciated by histological
examination in any of the surgical tissues.
We hypothesized that a potential mechanism of initiation
of myxoid degeneration was tumor apoptosis. Therefore, we
assessed matched pre and post-imatinib tumor tissue for
TUNEL. Ten of 14 pretreatment biopsies (4 biopsy
TABLE 1 Patient and tumor characteristics
Characteristic
Age (years)
Mean (95% confidence) 59 (7)
Tumor size (cm)












Small bowel 6 32
Disease status
Primary, no metastasis 13 68
Primary, with metastasis 2 11
Local recurrence, with metastasis 1 5
Recurrence, metastatic 3 16
Randomization (duration of preoperative imatinib)
3 days 7 36
5 days 6 32
7 days 6 32
GIST genotype
Kit exon 11 mutation 14 74
Kit exon 9 mutation 1 5
PDGFR-a exon 12 mutation 2 11
Kit exon 11 and PDGFR-a exon 12 mutation 1 5
Wild typea 1 5
a Wild type, no mutations found in exons analyzed
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specimens were inadequate) and 17 of 17 surgical tumor
specimens were analyzed for apoptosis (Fig. 2). Rare
TUNEL-positive cells were seen in the pre-imatinib tissue.
However, numerous TUNEL-positive cells were observed
in the post-imatinib surgical specimens with an absolute
increase of 12% for matched tissues (Table 4A).
TABLE 2 (A) Types of organ resections performed in patients undergoing complete resection of their GISTs after preoperative imatinib. (B)
Comparison of surgical characteristics and morbidities in patients treated with or without preoperative imatinib. MDACC ID030023 patients
received 3–7 days imatinib prior to surgical resection
(A)
Characteristic (n = 17, MDACC ID03-0023) No. %
Organ resectiona
Partial gastrectomy 10 59
Partial duodenectomy 2 12
Partial jejunectomy 4 24
Partial colectomy 4 24
Partial mesentectomy 3 18
Partial omentectomy 3 18
Partial hepatectomy 2 12
Distal pancreatectomy 2 12
Splenectomy 2 12
Adrenalectomy 1 6
Multi-organ resection 9 53
Patients requiring transfusion 7 41
Postoperative ICU monitoring 3 18
Mean Range
Tumor size (cm) 9 1–23
EBL (mL) 735 25–3,600
Transfusion volume (mL)b 1,230 500–2,500
Duration of hospital stay (days) 10 5–15
(B)
Characteristic MDACC ID030023 Imatinib-Naı¨ve (n = 27) p-value
Mean ±SD Mean ±SD
Tumor size (cm) 9.5 6.3 10.2 6.5 0.81
EBL (mL) 735.3 913.7 605.8 685.3 0.58
n % n %
Disease stage at surgery
Primary 12 71 17 63 0.75
Metastatic/recurrent 5 29 10 37
Need for blood transfusion
No 10 59 17 63 1.0
Yes 7 41 10 37
Perioperative adverse events
No 14 82 15 56 0.1
Yes 3 18 12 44
Imatinib-naı¨ve, retrospective cohort of GIST patients who underwent complete resection without prior imatinib therapy; ICU, intensive care unit;
EBL, estimated blood loss; SD, standard deviation
a Nine of 17 patients required multi-organ complete and/or partial resection of adjacent tissues to remove all gross disease. Thus, the total
number of organ resections is greater than 17
b Only seven patients required a blood transfusion during surgery
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Moreover, the rate of tumor cell apoptosis was found to
be dependent on the duration of preoperative imatinib
therapy (Table 4B). Tumor cell apoptosis increased incre-
mentally with duration of imatinib, where patients treated
for 7 days with preoperative imatinib had the greatest rate
of tumor cell apoptosis (15%, p = 0.04).
A high rate of TUNEL-positive cells in the resected
tumor specimens tended to be associated with dCT
response; however, this trend did not reach statistical sig-
nificance (p = 0.13). Interestingly, PET response by either
response criteria had no association with GIST cell
apoptosis.
Patients with tumors harboring kit exon 11 mutations had
a 14% increase in tumor cell apoptosis after preoperative
imatinib (p = 0.03) (Table 4C). Conversely, the one patient
with tumor harboring a kit exon 9 mutation had no increase
in apoptosis with imatinib therapy of 600 mg daily.
Disease-Free Survival
At the time of this analysis, eight (42%) patients have
successfully completed 2 years of postoperative imatinib.
Three (16%) patients continue to take postoperative i-
matinib on the study. Eight (42%) patients discontinued
imatinib prior to completing 2 years of postoperative i-
matinib: four owing to toxicity, two due to withdrawal of
consent, and two being lost to follow-up.
With median follow-up of 32 months, median duration
of DFS was 46 months (Fig. 3). Actuarial DFS rates were
94% and 87% at 1 and 2 years, respectively. Six (32%) of
the 19 patients have had a recurrence, but no patients have
died. Randomization to 3, 5, or 7 days of preoperative i-
matinib did not affect DFS (p = 0.71).
Interestingly, all patients who had a recurrence on the
study had disease that originated in the small bowel.
Moreover, these patients either had a large tumor burden
([10 cm) or presented with metastatic and/or recurrent
disease. Not surprisingly, larger tumor size predicted
shorter DFS (p = 0.02). There was a trend between longer
DFS and response measured by dCT and higher levels of
TABLE 3 Grade 3 and 4 adverse events experienced by patients.
Adverse events are separated based on treatment phase















Total grade 3/4 events 1 1 10
Patients w/grade 4 events 1 1 1
Preop., adverse events during 3–7 days of neoadjuvant imatinib; Pe-
riop., events during surgery and/or prior to starting postoperative
imatinib; Postop., events after starting adjuvant imatinib. Numbers in
bold indicate grade 4 adverse events. Numbers in italic indicate grade
3 adverse events
FIG. 1 Representative radiographic and functional imaging of GIST
(arrows). (a) contrast-enhanced CT before and after preoperative
imatinib. Some hypodensity within the tumor can be appreciated in
presurgical scans compared with baseline scans. (b) 18FDG-PET
before and after preoperative imatinib. Black indicates sites of 18FDG
accumulation. Complete abrogation of avid disease can be appreci-
ated in this representative patient in latter scans. (c) dCT blood flow
reconstruction before and after preoperative imatinib. Red indicates
blood flow similar to the abdominal aorta; other colors indicate blood
flow less than the abdominal aorta, with blue and black representing
the least blood flow. A decrease in the amount of red within the tumor
in latter scans compared to pre-imatinib scans indicates a decrease in
tumor blood flow in response to imatinib
Preoperative plus Postoperative Imatinib in GIST 915
tumor apoptosis, but neither reached statistical signifi-
cance. Moreover, PET response was not predictive of DFS
duration.
All six patients who had tumor recurrence had stopped
taking imatinib due to completion of the study, noncom-
pliance, or toxicity at the time of the recurrence. Five of
these six patients harbored kit exon 11 mutation and were
treated for 24, 24, 24, 8, and 15 months postoperatively.
The other patient harbored a kit exon 9 mutation and was
treated for 24 months postoperatively. Median time to
disease progression for these patients after discontinuation
of imatinib was 4 months. However, the likelihood of
recurrence was not associated with whether a patient was
receiving imatinib (p = 0.99), accounting for the fact that
the actual schedule of receiving or not receiving imatinib
over time varied between patients.
FIG. 2 Histologic evaluation of tumor tissue and TUNEL assay.
Matched hematoxylin and eosin (H&E) and immunofluorescence of a
representative frozen biopsy and surgical specimen from a single
patient treated for 5 days with preoperative imatinib. Hypercellular,
hyperchromic tissue can be appreciated in both the biopsy and
surgical specimens. TUNEL assay indicates that tumor cells under-
went apoptosis after 5 days of imatinib: blue, nuclei stained with
DAPI; green, fluorescein isothiocyanate (FITC) tag of positive
TUNEL reaction; merge, overlay of blue and green indicating nuclei
undergoing apoptosis
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No patient recurred at the cutaneous site of tumor biopsy
but rather in the peritoneum (three) and at hepatic sites
(three). The five patients that restarted imatinib therapy
(one of these patients was lost to follow-up) had a sub-
sequent response as assessed by contrast-enhanced CT.
DISCUSSION
We found that imatinib therapy appears to be safe when
given to GIST patients preoperatively, including hours prior
to surgical resection. Furthermore, we provide direct evi-
dence that radiographic response can be observed in the first
week of therapy and that tumor cell apoptosis increases
incrementally with duration of preoperative imatinib
therapy. Lastly, we show that postoperative administration
of imatinib improved duration of DFS in our GIST patients
at 1 and 2 years compared with that in historical controls
(ten). Thus, patients undergoing resection of their GISTs
may be considered for therapy with imatinib to prolong
disease-free survival.
It is our belief that the molecular mechanisms of i-
matinib efficacy are initiated prior to detectable
histopathologic cytoreduction. Thus, we chose to treat
patients for 3, 5, or 7 days in the hope of demonstrating
time-dependent molecular and/or functional changes
without cytoreduction. Our data demonstrate that, within
3–7 days of imatinib therapy, no cytoreduction is appre-
ciable histologically, yet we found no correlation between
functional radiographic imaging and apoptosis of tumor
cells. These findings suggest the radiographic responses
observed when a GIST patient is treated with imatinib are
not due entirely to GIST cell death.
Interestingly, the one patient without an increase in
tumor cell apoptosis harbored a kit exon 9 mutation and
was treated with only 600 mg daily imatinib. This finding
suggests the possibility that treating patients harboring
exon 9 mutation with 600 mg daily imatinib may be sub-
optimal as seen in patients with metastatic disease treated
with 400 mg daily doses.20
As evidenced by dCT, tumor blood flow decreases in
most patients within 3–7 days of initiation of imatinib
therapy. An antivascular effect of imatinib in GIST may
play a role in radiographic responses, surgical outcomes,
and perhaps patient survival. Multiple mechanisms
explaining this phenomenon have been suggested. Nitric
oxide production via nitric oxide synthase may be a
downstream effector of kit and abrogated in response to kit
inhibition, leading to collapse of the vascular architec-
ture.21,22 Alternatively, imatinib may target kit and/or
PDGFR signaling in tumor-associated endothelial cells or
pericytes.23–25
The American College of Surgeons Oncology Group
(ACOSOG) is evaluating adjuvant imatinib versus placebo
TABLE 4 Summary of TUNEL assay findings. (A) Average amount
of TUNEL-positive nuclei found in all patient tumor biopsies (pre-
imatinib) and surgical tissue (post-imatinib) and the mean absolute
change in apoptosis due to preoperative imatinib. (B) Mean incre-
mental increase in apoptosis with duration of preoperative (Pre-op)
imatinib. (C) Change in apoptosis in response to preoperative imatinib
based on patient tumor genotype
(A)
% Apoptosis (mean) Range
Pre-Imatinib (n = 10) 2 0–6
Post-Imatinib (n = 16) 11 3–33
Absolute change (n = 10) 12 0–33
(B)










kit exon 11 7 14 1–33 0.03
kit exon 9 1 0 NA NA
PDGFR-a exon 12 1 8 NA NA
kit exon 11 and
PDGFR-a exon 12
1 11 NA NA












FIG. 3 Disease-free survival. Kaplan–Meier plot of DFS versus time
(months) since recruitment to trial. Median DFS = 46 months. Tick
marks = patients censored
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for primary GIST. Preliminary results demonstrate a DFS
rate of 97% at 1 year for patients receiving imatinib com-
pared with 83% at 1 year following complete resection in
patients receiving placebo.26 Although our study included
higher-risk patients, we report a similar 1-year DFS rate of
94%, with a 2-year DFS rate of 87%. Although marginal,
the higher 2-year DFS rate in our study may be due to
treatment of patients with postoperative imatinib for 2 years
as compared with only 1 year in the ACOSOG study. Thus,
our study is supported by preliminary prospective and ret-
rospective data showing that adjuvant imatinib extends DFS
compared with surgery alone.26,27 Moreover, our findings
corroborate the preliminary data that larger tumor size
predicts shorter DFS for patients with a resected GIST
treated with imatinib postoperatively.26 This implies that
patients with large tumor burden ([10 cm in diameter) may
benefit from longer duration of adjuvant imatinib.
Importantly, not a single patient in this study had a
recurrence while receiving postoperative imatinib therapy.
This observation is interesting when considered in the
context of a randomized discontinuation study that found
patients with metastatic GIST who responded to imatinib
therapy had a markedly increased risk of progression upon
discontinuation of imatinib.28 Moreover, anecdotal studies
have found that residual quiescent tumor cells are observed
in tumors from GIST patients that have been resected after
response to imatinib.28–30 Thus, our results suggest that the
action of imatinib may be both cytotoxic by evidence of
apoptosis and cytostatic as observed in other studies that
have found quiescent GIST cells. It is possible that imati-
nib therapy, even in the adjuvant setting, should be
continued until toxicity, recurrence, or progression occurs.
Hopefully ongoing and future clinical trials will adequately
determine the duration of postoperative imatinib therapy.
Collectively, our study is the first prospective, random-
ized trial to show the safety and efficacy of combining
preoperative with postoperative imatinib. We are the first
to report early decreases in both tumor cell glucose
metabolism by FDG-PET and tumor blood flow by dCT as
well as a time-dependent increase in tumor cell apoptosis
after imatinib.
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